Jazz Pharmaceuticals has entered into an exclusive licensing agreement with Zymeworks' subsidiary, Zymeworks BC to develop and commercialise the latter’s HER2-targeted bispecific antibody, Zanidatamab.
Charles River Laboratories International and Nanoscope Therapeutics have announced a collaboration to manufacture gene therapies for vision disorders.
Eiger BioPharmaceuticals has announced that it will not seek emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for peginterferon lambda to treat mild-to-moderate Covid-19 patients.
Alexion, AstraZeneca Rare Disease has signed a deal to buy genomic medicine company LogicBio Therapeutics.
AeroRx Therapeutics has collaborated with HCmed Innovations to develop a long-acting beta-agonist (LABA) / long-acting muscarinic antagonist (LAMA) combination solution to treat chronic obstructive pulmonary disease (COPD).
Vanda Pharmaceuticals signed a research and development collaboration agreement with OliPass to jointly develop antisense oligonucleotide (ASO) therapeutics.
Arsenal Biosciences and Genentech have entered a multi-year collaboration for identifying features of T-Cell therapies for oncology.
Clinical-stage biopharmaceutical firm Sciwind Biosciences has signed a research partnership agreement with RNAi therapeutics company SynerK for the joint development of novel therapeutics to treat liver and metabolic diseases.
NETRIS Pharma, Orano and Centre Léon Bérard (CLB) have entered into a scientific collaboration agreement for the development of new antibody radio-conjugates to treat cancer.
The US Food and Drug Administration (FDA) has accepted for priority review Seagen’s supplemental New Drug Application (sNDA) seeking accelerated approval for its medicine tukysa (tucatinib) along with trastuzumab to treat colorectal cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.